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1ABSTRACT
Identification of tumorigenesis related signaling pathways in the tumors 
with nuclear β-catenin overexpression
Minhee Park
Department of Medical Science
The Graduate School, Yonsei University
(Directed by Professor Hoguen Kim)
Mutations of β-catenin, CTNNB1, have been reported in various cancers,
including colorectal cancer, breast cancer and lung cancer. Most β-catenin
mutations are located in exon 3 of β-catenin genes, which lead to 
stabilization of β-catenin by blocking the destruction complex of β-catenin. 
In colorectal cancers, APC mutations are detected in 70-80% of colon 
cancers and β-catenin mutations are mutually exclusive and detected in about 
5% of the colorectal cancers. Although the involvement of APC mutations in 
the altered Wnt/β-catenin pathway activity is well documented, the 
functional relevance between the deregulated Wnt/β-catenin signaling
pathway and β-catenin mutations has not yet been fully understood in colon 
cancers. Also, the molecular significances of β-catenin mutations in the other 
2cancers are not fully understood. Unlike colorectal carcinomas, nearly all of 
solid-pseudopapillary neoplasm (SPN) exhibit somatic mutation in exon3 of 
β-catenin, which results in abnormal nuclear accumulation (overexpression) 
of β-catenin. Although β-catenin mutation and activation of the Wnt/β-
catenin signaling pathway have been implicated in the pathogenesis of SPN, 
the molecular regulatory networks remain poorly understood.
To identify the altered pathways by nuclear overexpression of β-catenin in 
tumors, colon cancer and SPN were selected as study models. β-catenin
mutation is responsible for the development of a small subset of colon 
cancers, while development of SPN is solely driven by β-catenin mutation. 
The molecular significances of nuclear β-catenin overexpression were 
compared in colon cancer as a model of nuclear β-catenin overexpression by 
altered genes involved in β-catenin degradation, and SPN as a model of 
nuclear β-catenin overexpression by β-catenin mutation. Since nuclear β-
catenin shows heterogeneous expressions in colon cancers, the colorectal 
tumors were classified by percentage of nuclear β-catenin and identified a 
subset of colon cancers by comparing gene expression profiles in the colon 
cancers showing heterogeneous expression of nuclear β-catenin. As a result, 
it was found that overexpressed nuclear β-catenin activates genes involved in 
Wnt/β-catenin signaling, Notch signaling, Hedgehog signaling and ECM-
receptor interaction in colon cancer. 
To identify gene subsets associated with nuclear β-catenin overexpression 
by β-catenin mutation, mRNA expression profiles of SPN and other 
pancreatic tumors (pancreatic adenocarcinomas and neuroendocrine tumors)
were performed. All SPNs harbor β-catenin mutation, while the other 
pancreatic tumors harbor no β-catenin mutation. Unsupervised clustering 
3analysis of mRNA expression distinguished SPNs as a distinct type of 
pancreatic tumor. Analysis of differentially expressed genes in SPN 
demonstrated that genes involved in Wnt/β-catenin, Hedgehog and androgen 
receptor signaling pathways as well as epithelial-mesenchymal transition 
were activated in solid-pseudopapillary neoplasms.
Finally, the altered expression level of genes involved in three activated 
signaling pathways was confirmed by using cells transfected with β-catenin
constructs. Transfection of mutant β-catenin constructs resulted in the 
translocation of androgen receptor into the nucleus and up-regulated several 
molecules involved in Wnt/β-catenin, Notch and Hedgehog signaling.
In conclusion, overexpression of nuclear β-catenin commonly or selectively 
affects the signaling pathways of the Wnt/β-catenin, Notch, Hedgehog and 
androgen receptor, and contributes to the tumorigenesis of colon cancers and 
SPN.
-----------------------------------------------------------------------------------------------------
Key words : β-catenin, colon cancer, solid-pseudopapillary neoplasm (SPN), gene 
expression, Wnt/β-catenin signaling, Notch signaling, Hedgehog signaling
Abbreviation : APC; Adenomatous polyposis coli, GSK3β; Glycogen synthase 
kinase 3 beta, AR; androgen receptor SPN; Solid-pseudopapillary neoplasm, PCA; 
Pancreatic adenocarcinoma, NET; Neuroendocrine tumor, DEG; Differentially 
expressed gene, EMT; Epithelial mesenchymal transition
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I. INTRODUCTION
Tumorigenesis is a complicated process, comprising multiple cascades of genetic 
aberrations that promote or inhibit the cell cycle, proliferation, and apoptosis. In 
normal cells, proto-oncogenes regulate the cell cycle and differentiation. However, 
if mutated or overexpressed, these oncogenes promote excessive cell proliferation. 
Typically, single oncogene is involved in only one specific step in tumorigenesis, 
such that multiple oncogenes are responsible for the entire tumorigenesis process. 
One oncogene known to be relevant to the development of various cancers is β-
catenin, a component of the cell adhesion complex, including E-cadherin, and a key 
molecule in the Wnt/β-catenin signaling pathway.1,2
In general, Wnt/β-catenin signaling is important to cell proliferation, 
differentiation, and embryonic development.1,3 Regulation of the Wnt/β-catenin 
pathway depends on the interaction between the frizzled receptor and Wnt ligand. In 
the absence of Wnt, the destruction complex composed of adenomatous polyposis 
5coli (APC), Axin, glycogen synthase kinase (GSK) and casein kinase 1 (CK1) binds 
to and phosphorylates β-catenin at Ser-33, Ser-37, Thr-41, and Ser-45, making it 
recognizable by the ubiquitin ligase, β-TrCP. Degradation of β-catenin is then 
carried out by the ubiquitin-proteasome system. Meanwhile, in the presence of Wnt, 
activated frizzled receptor phosphorylates the dishevelled protein, stabilizing β-
catenin and allowing it to accumulate in the cytoplasm.4 Once accumulated, β-
catenin binds to LEF/TCF transcription factors, and this complex is translocated 
into nucleus, where it leads to the upregulation of Wnt target genes, such as c-myc
and cyclinD1.5,6
The Wnt/β-catenin signaling pathway, itself, plays key roles in multiple 
biological processes. However, it can contribute to tumorigenesis and stem cell 
maintenance in combination with other pathways, such as Notch and Hedgehog 
signaling pathways: briefly, increased JAG1 expression by β-catenin induces 
activation of the Notch pathway, which can also be activated upon JAG2
stimulation by Gli molecules.7,8
In addition to mutations in APC genes, mutation of β-catenin mutation can also 
activate abnormal Wnt/β-catenin signaling. β-catenin mutations have been 
reported in various cancers, including colorectal cancer, breast cancer, lung 
cancer ,and glioblastoma.9,10 Most β-catenin mutations are reportedly detected in 
exon 3 of CTNNB1 genes that encode β-TrCP binding regions, blocking degradation 
of β-catenin and resulting in constant activation of Wnt/β-catenin signaling
pathway.5,6 In colorectal cancers, dysregulation of the Wnt/β-catenin signaling 
pathway caused by APC mutations is detected in 70-80% of colorectal cancers, 
while β-catenin mutations are detected in about 50% of tumors with wild-type 
APC.11-14 Although the frequency of mutations in β-catenin is about 5% for all colon 
cancers, varying expression levels of nuclear β-catenin are observed in colon cancer 
tissues (0-100%).15
6Most previous studies on Wnt/β-catenin signaling in cancer have used indirect 
mouse models, including APC Min mice or β-catenin exon 3 deletion mice, to study 
the effects of activated Wnt/β-catenin signaling. 7,16 However, the regulatory 
mechanisms of β-catenin proposed by these studies remain controversial: for 
example, indirect mouse models of APC mutations alone or Wnt-induced 
stabilization of β-catenin failed to show explicit nuclear accumulation of β-
catenin.17-20 Moreover, although the involvement of APC mutations in altered 
Wnt/β-catenin signaling is well documented, the functional relevance of the 
altered Wnt/β-catenin signaling and β-catenin mutations has not yet been fully 
elucidated in colon cancers. Also, the molecular impact of nuclear accumulation of 
β-catenin in other cancers is not fully understood.
Solid-pseudopapillary neoplasms (SPN) are characterized by mutations in exon 3 
of β-catenin and abnormal β-catenin nuclear accumulation.21-23 The molecular 
genetics of SPN has recently become one of the best understood among all human 
tumors.24 SPN is classified as a distinct phenotype due to its characteristic 
clinicopathologic features and distinct immunophenotype, compared to other 
pancreatic tumors that show no mutations in β-catenin.25,26 Although β-catenin
mutation and activation of the Wnt/β-catenin signaling pathway have been 
implicated in the pathogenesis of solid-pseudopapillary neoplasm, the molecular 
regulatory networks of this tumor remain poorly understood.
To elucidate the pathways altered by overexpression of nuclear active β-catenin in 
tumors, colon cancer and SPN were selected as study models. Since β-catenin
mutation is responsible for the development of a subset of colon cancers and since 
most abnormal nuclear β-catenin overexpression is induced by altered genes, 
especially APC mutation, colon cancers were selected as a model of heterogeneous 
overexpression of nuclear β-catenin caused by alteration in genes involved in β-
catenin degradation. 
Meanwhile, SPN was chosen as a model of homogenous overexpression of nuclear 
7β-catenin caused by mutation in β-catenin. In the present study, colorectal tumors 
were classified according to levels of nuclear β-catenin overexpression and 
pancreatic tumors according to β-catenin mutation. Then, mRNA expression 
profiles for these tumors were analyzed. Although the colon cancers showing high 
nuclear overexpression of β-catenin is not included in specific one cluster of 
grouped samples, overexpressed nuclear β-catenin activates genes involved in 
Wnt/β-catenin signaling, Notch signaling, and ECM-receptor interactions. 
Additional analysis of differentially expressed genes in SPNs harboring β-catenin
mutation revealed that Wnt/β-catenin, Hedgehog, and androgen receptor signaling 
pathways, as well as genes involved in epithelial-mesenchymal transition (EMT), to 
be activated in SPNs.
8II. MATERIALS AND METHODS
1. Tissue samples and RNA preparation
The 101 Colorectal cancer tissue samples, 35 matched normal colon tissues, 14 
solid-pseudopapillary neoplasms (SPN), six pancreatic adenocarcinomas (PCA), six 
neuroendocrine tumors (NET), and five non-neoplastic pancreatic tissue samples 
were used in this study. The specimens were obtained from the archives of the 
Department of Pathology, Yonsei University, Seoul, Korea, and from the Liver 
Cancer Specimen Bank of the National Research Resource Bank Program of the 
Korean Science and Engineering Foundation of the Ministry of Science and 
Technology. Patient data were collected retrospectively from hospital records. All 
colon cancer patients had undergone colorectal resection between 2006-2012 and 
pancreatic tumor patients had undergone pancreatic resection between 2001-2011 
and fresh snap-frozen samples were obtained immediately at the time of surgery. 
All carcinoma samples comprised B70% tumor cells, and none of the patients had 
received neo-adjuvant chemotherapy. Authorization for the use of these tissues for 
research purposes was obtained from the Institutional Review Board of Yonsei 
University of College of Medicine.
Total RNA was extracted using Trizol (Invitrogen Life Technologies) according to
the manufacturers’ protocol. After DNase digestion and other clean-up procedures, 
RNA samples were quantified, aliquoted, and stored at -80℃ until use. For quality 
control, RNA purity and integrity were evaluated by denaturing gel electrophoresis, 
measurement of the A260/280 ratio, and analyzed using the 2100 bioanalyzer 
(Agilent Technologies). For all samples, the RNA integrity number scores were >9.5. 
2. Gene expression Analysis
For DNA microarray hybridization, RNA was pooled by mixing equal amounts of 
total RNA. Biotin-labeled cRNA targets were synthesized starting from 1.5 μg of 
total RNA. Double-stranded cDNA synthesis was performed using the Illumina 
TotalPrep RNA Amplification Kit (Illumina), while biotin-UTP-labeled antisense 
9RNA was transcribed in vitro using Ambion’s Kit (Ambion Life Technologies). All 
steps of the labeling procedure were performed according to the manufacturers’ 
protocol. Microarray experiments were conducted on the HumanHT-12 v4 Sentrix 
Expression BeadChip (Illumina). Hybridization of labeled cRNA to the BeadChip, 
washing, and scanning were performed according to the Illumina Bead Station 
500X manual.
3. mRNA expression data preparation and statistical analysis
Raw data were extracted using the software provided by the manufacturer 
(Illumina Genome Studio v2011.1 (Gene Expression Module v1.9.0)). Expression 
intensities were normalized using quantile normalization techniques.27 Using the 
normalized intensities, differentially expressed genes between normal and tumor
tissues were determined using the integrated statistical method previously 
reported.28 Briefly, (1) two independent tests were performed: Student’s t-test and 
log2–median-ratio test; (2) adjusted P-values from each test were computed using an 
empirical distribution of the null hypothesis that the means of the genes were not 
different, which was obtained from random permutations of the samples; (3) the P-
values from the two tests were combined to compute the overall P-values using 
Stouffer’s method29 and (4) differentially expressed genes were selected as those 
with p<0.05 or 0.01 and a fold change >1.5. Finally, functional enrichment analysis 
of the differentially expressed genes was performed using DAVID software30 to 
identify GO biological processes and KEGG pathways represented by the genes in 
individual clusters with statistical significance.
4. TMT Labeling, LC-MS/MS Analysis and Peptide identification 
Denaturation and reduction of the sample was performed in 8M urea, 5mM DTT 
and 25mM NH4HCO3 (pH 8.0) for over 30min. The urea was diluted to a conc. 1M 
with NH4HCO3 and then digested with modified trypsin. (37°C, 16hr) Each 100μg 
sample in 20μl 500mM TEAB was reduced, alkylated, digested, and labeled with 
10
TMT reagents. Nano-high-performance liquid chromatography (nano-LC) analyses 
were performed using an Easy n-LC 1000 system. A C18 nanobore column (150mm 
× 0.1mm, 3mm pore size) was used for peptide separation. LTQ-Orbitrap MS was 
used for either identification or quantification of peptides. The Xcalibur (v2.1) used 
to generate peak lists. Proteome Discoverer software(v1.4) was used for protein 
identification and quantification. (with UniProt and by calculating the ratio between 
the peak areas of the TMT reporter groups) All quantitative results were normalized 
using medians (minimum protein count: 20). Reverse sequences were used for 
evaluation of the false discovery rate (FDR<1%). 
5. Cell culture and plasmids transfection
For the transfection assay analysis, HEK293 and RKO cells were used. Cells were 
maintained in DMEM, or RPMI (HyClone) containing 10% FBS (HyClone) and 1% 
penicillin/streptomycin at 37℃ in a 5% CO2 incubator according to ATCC 
guidelines. The β-catenin wild-type and mutant (S33A, S37A, T41A and S45A) 
construct were used in this study. 293T and RKO cells were cultured in 60-mm 
dishes and were transiently transfected with 3ug of each specific plasmid using 
Lipofectamine 2000 according to the manufacturer’s protocol. Cells were harvested 
48 hours later and were used for RNA extraction and protein purification.
6. Construction of expression plasmid vectors
The β-catenin gene including CDS was cloned into a pLECE3 vector conjugated 
with EGFP. For evaluating the effect of β-catenin mutant, β-catenin S33A, S37A, 
T41A and S45A mutant constructs were generated by substitution mutagenesis at 
each 33th, 37th, 41th and 45th amino acid of wild-type (WT) β-catenin construct.
7. RT-PCR and real-time PCR
Total RNAs were isolated from cells using illustra RNAspin Mini kits (GE 
Healthcare, Fairfield, CT, USA) and reverse transcription was performed with 2μg 
11
of RNA. Real-time PCR was performed using the ABI PRISM 7500 Sequence 
Detector (Applied Biosystems) and SYBR Premix Ex TaqII (TaKaRa), according to 
the manufacturers’ guidelines. The mRNA expression levels are presented as means 
± S.D. from three independent experiments. Melting curves of PCR products were 
assessed for quality control. The sequences of the primers used are listed in Table 1.
Table 1. Primers used for RT-PCR and qRT-PCR
Gene Direction Sequence
CTNNB1
Forward 5'- AGCTTCCAGACACGCTATCAT
Reverse 5'- CGGTACAACGAGCTGTTTCTAC
Axin2
Forward 5'- CAACACCAGGCGGAACGAA
Reverse 5'- GCCCAATAAGGAGTGTAAGGACT
GLI2
Forward 5'- CCCCTACCGATTGACATGCG
Reverse 5'- GAAAGCCGGATCAAGGAGATG
CDH1
Forward 5'- CGAGAGCTACACGTTCACGG
Reverse 5'- GGGTGTCGAGGGAAAAATAGG
CDH2
Forward 5'- AGCCAACCTTAACTGAGGAGT
Reverse 5'- GGCAAGTTGATTGGAGGGATG
AR
Forward 5'- GACGACCAGATGGCTGTCATT
Reverse 5'- GGGCGAAGTAGAGCATCCT
18S ribosomal
Forward 5'- GTAACCCGTTGAACCCCATT
Reverse 5'- CCATCCAATCGGTAGTAGCG
GAPDH
Forward 5'- AAGGTGAAGGTCGGAGTCAAC
Reverse 5'- GGGGTCATTGATGGCAACAATA
8. Western blot
Total proteins were prepared using passive lysis buffer (Promega) and 40 μg of 
each protein sample were separated by SDS-PAGE and transferred to PVDF 
membranes. After blocking with TBST containing 5% skim milk, blots were 
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incubated for 1hr at room temperature with primary antibodies against WIF-1, 
GSK3β (Santa Cruz biotechnology), GLI2, N-cadherin (Abcam), β-catenin, AR, E-
cadherin (BD Bioscience), Axin, phospho-GSK3β, CyclinD1, β-actin (Cell 
signaling), phospho-β-catenin (Millipore) and GAPDH (Trevigen, Gaithersburg, 
MD, USA). HRP-conjugated secondary antibody (Santa Cruz technology) was used. 
9. Immunohistochemistry
Paraffin-embedded tissue blocks were cut into 4-μm sections. 
Immunohistochemical analysis was performed using a Ventana XT automated 
stainer (Ventana) with antibodies against β-catenin (diluted 1:100, BD Biosciences), 
WIF-1 (diluted 1:50, Santa Cruz biotechnology), GLI2 (diluted 1:100, Abcam), 
androgen receptor (prediluted; Roche), E-cadherin for extra-cellular domains 
(diluted 1:100, Dako) and intracellular domains (diluted 1:200, BD Biosciences) 
and N-cadherin (diluted 1:50, Abcam).
10. Immunofluorescence microscopic analysis
Subcellular localization of mutant β-catenin was analyzed by immunofluorescence 
staining. The cells attached to glass coverslips were rinsed with PBS followed by 
fixation with 4% paraformaldehyde for 15min, and permeabilization in 0.3% Triton 
X-100 in PBS. Upon the removal of Trixon X-100, cells were again rinsed. 
Nonspecific sites were blocked with 2% bovine serum albumin for 1hr. After 
blocking, the medium was replaced with the respective primary antibodies, and cells
were incubated overnight. Cells were then washed and incubated for 1hr with the 
appropriate fluorescently labeled secondary antibodies. All images were obtained 
using an LSM700 confocal microscope (Carl Zeiss).
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III. RESULTS
1. Identification a subset of colon cancers with nuclear β-catenin 
overexpression
Nuclear overexpression of β-catenin was identified in colorectal tumors, especially 
at tumor budding cells. In the normal colon mucosa, β-catenin expression was 
localized to the membrane of normal colonocytes, while β-catenin expression was 
increased or accumulated in nucleus in some of colon adenocarcinomas. Nuclear β-
catenin was not uniformly expressed, expressed in a wide range between 0 (negative) 
and 60%, especially high nuclear expression was verified in over 50% of tumor 
budding cells (Table 2 and Figure 1). To identify altered gene subsets and pathway 
Figure 1. Representative immunohistochemical analysis of β-catenin expression.
Tumors showed negative β-catenin expression in the nucleus of tumor cells, weak 
(1-3%), moderate (5-25%) and high nuclear expression of β-catenin (>30%). 
Figures are X200 and X400. Negative shows staining of β-catenin only at the 
membrane, but no staining in the nucleus. Weak, moderate or high show staining of 
β-catenin in the nucleus.
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induced by nuclear β-catenin overexpression, colon cancer samples are classified by
percentage of β-catenin nuclear overexpression and subsequently analyzed based on 
the classified sample groups. Normal colon epithelium showed only membranous 
expression with β-catenin. In the colorectal cancers, however, three distinct 
expression patterns were seen: i) negative expression similar to normal tissue 
showing only membranous expression without nuclear expression, ii) weak nuclear 
expression of β-catenin (1-3% of tumor cells), iii) moderate nuclear expression of β-
catenin (5-25%) and iv) high nuclear expression of β-catenin with 30% as the high 
expression cutoff.
2. Overexpression of nuclear β-catenin correlates with frequent metastasis 
after operation
To identify the altered pathways by nuclear β-catenin overexpression, gene 
expression analysis of colorectal cancer tissues were performed as a model with
heterogeneous nuclear β-catenin expression. As a result, I found that colon samples 
were nicely clustered into normal versus tumor group (Figure 2A). I also performed 
β-catenin mutation analysis using about 100 cases of colon cancers tissues and
Table 2. Number and proportion of colorectal cancers showing nuclear 
overexpression of β-catenin
β-catenin nuclear
accumulation (IHC result)
Number %
  Negative 33 32.7
  Weak (1-3%) 23 22.8
  Moderate (5-25%) 30 29.7
  High (≥30%) 15 14.9
Total cases 101 cases 100 %
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Figure 2. Hierarchical Clustering of gene expression profiles of colon cancers 
and β-catenin mutation analysis. Unsupervised hierarchical clustering analysis of 
gene expression. Red and green indicate transcript levels above and below the 
sample median, respectively. Complete separation of 35 normal colon tissues (red) 
and 101 colon cancers (skyblue) were evident based on gene expression profiles of 
colon cancers (A). The results of sequencing result of tumors with β-catenin 
mutation. β-catenin codon 41 mutations were detected in two cases (B). Two cases 
with β-catenin mutation were not positioned in the same complete linkage group (C).
found only 2 cases have β-catenin mutation in exon3 (Figure 2B). These two cases 
harboring β-catenin mutation were not positioned in the same group clustered by 
complete linkage analysis (Figure 2C and 3A). Except for 2 cases with mutations, 
further analysis was conducted to study the effect of nuclear overexpression of β-
catenin driven not only by β-catenin mutations, but also by indirect activation such 
as APC mutations.
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Figure 3. Hierarchical clustering analysis of mRNA expression profiles of 
colorectal tumors and clusters of differentially expressed genes. Red and green 
indicate transcript levels above and below the sample median, respectively. Blue 
and purple indicate colorectal tumors that show high and moderate nuclear 
expression of β-catenin, respectively (A). Clusters of differentially expressed genes 
showing all combination of differential expression in the three comparisons: High 
expression of nuclear β-catenin versus normal colon, Moderate and weak expression 
of nuclear β-catenin versus normal colon, and negative expression of nuclear β-
catenin versus normal colon. Red and green denote up- and down-regulated genes 
(|fold change|>1.5 and p-value<0.05 as cut-off ) (B).
Hierarchical cluster analysis using complete linkage did not distinguish tumors 
showing highly expressed nuclear β-catenin as tumors with weak or negative 
expression of nuclear β-catenin. Tumors with high nuclear overexpression of β-
catenin (>30%) is widely located in the clustered samples. (Figure 3A) Based on 
our analysis of dysregulated mRNAs in colorectal tumors showing more than 30% 
nuclear overexpression of β-catenin, I identified 291 up-regulated genes and 256
down-regulated genes compared to tumors with no nuclear expression of β-catenin 
(Figure 3B). Additionally the biological significance of nuclear β-catenin
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overexpression was related to the frequent post-operative metastasis (Figure 4A). 
The proportion of nuclear β-catenin level in colon tumor cells was higher in tumors 
with metastasis after operation than in tumors with no metastasis after operation
(Figure 4B). 
Figure 4. Correlation between nuclear β-catenin and metastasis. Ratio between
patients with metastasis and patients with no metastasis according to nuclear β-
catenin expression. Tumors with high nuclear β-catenin expression show more 
frequent metastasis after curative resection (A). Colon cancer patients with 
metastasis after curative resection showed high nuclear β-catenin staining compared 
to patients with no metastasis (B).
3. Nuclear β-catenin plays roles in Wnt/β-catenin signaling as well as 
regulation of cell development, cell adhesion and ECM-receptor interaction
To identify the signaling pathways associated with high nuclear β-catenin
overexpression, I analyzed which categories of gene ontology are associated with 
specifically upregulated or down-regulated genes in the cases with high expression 
of nuclear β-catenin by performing an enrichment analysis of GO biological process 
and KEGG pathways using DAVID software. GO biological process analysis 
demonstrated that 291 up-regulated genes are involved in Wnt/β-catenin signaling 
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Table 3. Functional categories with differentially up-regulated genes in high, 
moderate nuclear expression of β-catenin compared to negative nuclear 
expression of β-catenin
Category Term Count % p-value Benjamini
GOTERM_BP_FAT cell cycle 45 7.7 0.000052 0.022
GOTERM_BP_FAT RNA processing 45 7.7 3.9E-09 0.0000084
GOTERM_BP_FAT cellular response to stress 35 6 0.00013 0.039
GOTERM_BP_FAT DNA metabolic process 35 6 0.000014 0.0099
GOTERM_BP_FAT cell cycle process 34 5.8 0.00028 0.058
GOTERM_BP_FAT
response to DNA damage 
stimulus
30 5.1 0.0000039 0.0042
GOTERM_BP_FAT chromosome organization 26 4.4 0.0076 0.45
GOTERM_BP_FAT DNA repair 24 4.1 0.000021 0.011
GOTERM_BP_FAT mRNA metabolic process 24 4.1 0.001 0.12
GOTERM_BP_FAT mitotic cell cycle 23 3.9 0.0023 0.23
GOTERM_BP_FAT mRNA processing 23 3.9 0.00035 0.067
GOTERM_BP_FAT chromatin organization 22 3.7 0.0061 0.41
GOTERM_BP_FAT RNA splicing 22 3.7 0.00017 0.045
GOTERM_BP_FAT cell division 21 3.6 0.00074 0.11
GOTERM_BP_FAT regulation of cell cycle 21 3.6 0.0029 0.26
GOTERM_BP_FAT mitosis 15 2.6 0.0077 0.44
GOTERM_BP_FAT translational elongation 13 2.2 0.000057 0.02
KEGG_PATHWAY Axon guidance 7 2.2 0.039 0.55
KEGG_PATHWAY Purine metabolism 7 2.2 0.077 0.74
KEGG_PATHWAY Spliceosome 7 2.2 0.035 0.6
GOTERM_BP_FAT
Wnt receptor signaling 
pathway
11 1.9 0.0076 0.44
KEGG_PATHWAY Cell cycle 6 1.9 0.096 0.68
KEGG_PATHWAY Basal cell carcinoma 5 1.6 0.022 0.89
GOTERM_BP_FAT tRNA processing 9 1.5 0.0022 0.23
GOTERM_BP_FAT Notch signaling pathway 8 1.4 0.00096 0.12
GOTERM_BP_FAT
protein amino acid 
lipidation
7 1.2 0.0053 0.38
KEGG_PATHWAY Base excision repair 4 1.2 0.03 0.64
KEGG_PATHWAY Hedgehog signaling 4 1.2 0.095 0.72
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pathway
KEGG_PATHWAY
Pentose phosphate 
pathway
3 0.9 0.084 0.72
as well as Notch signaling, Hedgehog signaling, regulation of cell development, cell
adhesion and ECM-receptor interaction (Table 3), while 242 down-regulated genes 
are involved in focal adhesion, cell adhesion and MAPK signaling pathway.
4. All of SPN have mutation in exon3 of CTNNB1 and nuclear overexpression
of β-catenin
Mutation of SPN was detected by direct sequencing of PCR products. All of 14 
SPNs have mutation in exon3 of CTNNB1, while the pancreatic adenocarcinomas 
and neuroendocrine tumors have no mutation in exon3 of CTNNB1 (Table 4).
Immunohistochemistry analysis was performed to verify localization of β-catenin, 
and confirmed that strong β-catenin nuclear expression in all 14 SPNs, whereas no 
nuclear β-catenin expression was found in pancreatic adenocarcinomas or 
neuroendocrine tumors. (Figure 7C)
Table 4. Mutation status of solid-pseudopapillary neoplasm
Case 
no.
Mutation 
status
Case 
no.
Mutation 
status
Case 
no.
Mutation 
status
SPN
1 C97T
PCA
1 No mutation
NET
1 No mutation
2 C85T 2 No mutation 2 No mutation
3 G81A 3 No mutation 3 No mutation
4 G81T 4 No mutation 4 No mutation
5 G88T 5 No mutation 5 No mutation
6 C109T 6 No mutation 6 No mutation
7 G87A
8 A82G
9 C97G
10 C85G
11 G81A
12 C97T
13 C97G
14 G87A
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5. Unsupervised clustering analysis of mRNA expression distinguishes SPN as 
a distinct type of pancreatic tumor
As a first step in the molecular analysis of SPN, I examined whether the mRNA 
expression profiles are distinct among the different pancreatic tumors examined. 
The mRNA expression profiling was performed on 14 SPNs, two types of other 12 
pancreatic tumors without β-catenin mutation [six pancreatic adenocarcinomas
(PCA), six neuroendocrine tumors (NET), and five non-neoplastic pancreatic tissues] 
by using the Human HT-12 v4 Expression Bead Chip. The chip contains 47,231 
probes representing 31,332 annotated genes. Unsupervised hierarchical clustering 
analysis based on the 6,777 differentially expressed genes was performed by using 
the 6,777 differentially expressed genes relative to non-neoplastic samples. mRNA 
expression values were divided by the median value of five non-neoplastic 
pancreatic tissues. The clustering result represents that 26 tumor samples into 
separate three clusters according to the tumor type, SPN, PCA and NET compared 
to non-neoplastic pancreas, suggesting that these tissue types could be characterized 
by unique differential gene expression (Figure 5A).
6. Identification of characteristic signaling pathways associated with SPN
I then examined whether the SPN-specific up- and downregulated genes are 
associated with signaling pathways by performing an enrichment analysis of GO 
biological processes and KEGG pathways using DAVID software. GO biological 
processes enrichment analysis demonstrated that the SPN-specific upregulated
genes represent several signaling pathways, including the Wnt/β-catenin, Hedgehog, 
and androgen receptor signaling cascades (Table 5). KEGG pathway enrichment 
analysis also revealed an association with the Wnt/β-catenin and Hedgehog 
signaling pathways in addition to identifying other pathways represented by the 
upregulated genes (eg, ubiquitin-mediated proteolysis). GO biological process 
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Figure 5. Unsupervised hierarchical clustering analysis of mRNA expression 
profiles of pancreatic tumors and clusters with DEGs. Clustering analysis using 
the filtered 6777 differentially expressed genes in 26 pancreatic tumors composed 
of six pancreatic adenocarcinomas, 14 solid-pseudopapillary neoplasms, and six 
neuroendocrine tumors. Each mRNA expression value was divided by the median 
value of five non-neoplastic pancreatic tissues. Color bar gradient represents log2-
fold changes in each pancreatic tumor compared to non-neoplastic pancreas (A). 
The 25 clusters of differentially expressed genes (B). KEGG pathway enrichment 
analysis with SPN-specific up-regulated genes represent several signaling pathways, 
including the Wnt/β-catenin, Hedgehog, and androgen receptor signaling cascades 
(C). GO biological process analysis of up-regulated genes also demonstrated these 
three activated signaling pathways (D).
analysis of the downregulated genes demonstrated their association with cell 
motility, migration, and blood vessel development. Moreover, the KEGG pathways 
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represented by the downregulated genes included fructose and mannose metabolism, 
the MAPK signaling pathway, and endocytosis (Figure 6A and 6C). Notably, 
comparison of the GO biological process and KEGG pathways found in the 25 
differentially expressed genes clusters demonstrated that the genes specifically 
upregulated in SPNs were exclusively related to the Wnt/β-catenin, Hedgehog, and 
androgen receptor signaling pathways (cluster 5 in Figure 5B and Figure 6). I 
selected CTNNB1 and Axin2 to assess the Wnt/β-catenin signaling pathway, GLI2
for the Hedgehog pathway, and androgen receptor for the androgen receptor 
signaling pathway. E-cadherin (CDH1) and N-cadherin (CDH2) were chosen as 
representative genes of epithelial-mesenchymal transition. mRNA levels of these
selected genes were verified by quantitative RT-PCR. (Figure 7A). Marked 
upregulation of CTNNB1 was found in SPN, while only a slight increase was 
observed in pancreatic adenocarcinoma (PCA) and neuroendocrine tumor (NET) 
compared with non-neoplastic pancreatic tissues (Figure 6). Expression of Axin2, 
GLI2, and androgen receptor were markedly higher in SPN relative to PCA, NET, 
and non-neoplastic pancreatic tissues. E-cadherin, an epithelial marker, was 
downregulated, while N-cadherin was significantly upregulated in SPN relative to
non-neoplastic pancreatic tissues and PCA. I also validated β-catenin, WIF-1, GLI2, 
androgen receptor, E-cadherin, and N-cadherin expression by western blotting 
(Figure 7B) and immunohistochemistry (Figure 7C). Both western blotting and 
immunohistochemical analysis revealed increased levels of β-catenin, WIF-1, GLI2, 
androgen receptor, and N-cadherin, along with decreases in E-cadherin in SPNs. All 
SPNs showed increased β-catenin expression, whereas PCAs and NETs showed 
slightly increased β-catenin expression compared with non-neoplastic pancreas by 
western blot. WIF-1 protein was also highly expressed in SPN tumor tissues relative 
to matched normal pancreatic tissues by western blot. GLI2 was highly expressed in 
all SPNs and three out of six PCAs, but was not expressed in NETs and non-
neoplastic pancreas according to western blot. Androgen receptor was highly
expressed in all SPNs, but not expressed in PCAs, NETs, or non-neoplastic
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Figure 6. Gene ontology biological process (GOBP) and KEGG pathways 
represented by differentially expressed genes. Results of GOBP and KEGG 
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analysis. Red and green indicate the significance of GOBP enrichment by the up-
and down-regulated genes, respectively in SPN, NET, or PCA compared to non-
neoplastic pancreas. Color bar represent the gradient of -log10(P) where P indicates 
enriched P values calculated by the DAVID software. The dendrogram was 
generated by cluster analysis of -log10(P) values (A). KEGG pathway enrichment 
analysis with SPN-specific up-regulated genes represent several signaling pathways, 
including the Wnt/β-catenin, Hedgehog, and androgen receptor signaling cascades 
(B). GO biological process analysis of up-regulated genes also demonstrated these 
three activated signaling pathways (C).
Figure 7. Validation of differentially expressed genes in solid-pseudopapillary 
neoplasm by quantitative RT-PCR, western blotting and
immunohistochemistry. mRNA levels of CTNNB1 (β-catenin), Axin2, GLI2, 
androgen receptor (AR), CDH1 (E-cadherin) and CDH2 (N-cadherin) were verified 
by qRT-PCR. The expression level of each mRNA was normalized to that of 18s 
rRNA and arbitrarily set to 1. *p<0.05; **p<0.01 based on the Student’s t-test (A). 
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Protein levels of components of the Wnt/β-catenin, Hedgehog, and androgen 
receptor signaling pathways were assessed in solid-pseudopapillary neoplasm 
(SPN), non-neoplastic pancreatic tissues, pancreatic adenocarcinomas (PCA), and 
neuroendocrine tumors (NET) by western blot (B) and immunohistochemistry (C).
Table 5. List of Wnt/b-catenin, Hedgehog, and AR signaling-related genes up-
regulated in SPN
Official
symbol
Gene name
Fold
change
P value
Wnt/β-catenin signaling pathway 
  DKK4 dickkopf homolog 4 (Xenopus laevis) 300.66 3.7E-07
  WIF1 WNT inhibitory factor 1 74.77 1.3E-05
  NKD1 naked cuticle homolog 1 (Drosophila) 64.91 4.9E-06
  AXIN2 axin 2 31.44 1E-05
  FZD7 frizzled homolog 7 (Drosophila) 14.74 0.00011
  WNT2B wingless-type MMTV integration site family, member 2B 11.49 0.00017
  RUVBL1 RuvB-like 1 (E. coli) 9.34 0.00022
  WNT5A wingless-type MMTV integration site family, member 5A 8.12 0.00094
  NKD2 naked cuticle homolog 2 (Drosophila) 5.75 0.00329
  MAP3K7 mitogen-activated protein kinase kinase kinase 7 5.63 0.00035
  TCF7 transcription factor 7 (T-cell specific, HMG-box) 5.45 0.00063
  PPARD peroxisome proliferator-activated receptor delta 5.29 0.00029
  FZD2 frizzled homolog 2 (Drosophila) 4.69 0.00049
  NFAT5 nuclear factor of activated T-cells 5, tonicity-responsive 4.04 0.00117
  CTNNB1 catenin (cadherin-associated protein), beta 1, 88kDa 3.92 0.00331
  CCND3 cyclin D3 2.69 0.00264
  SMAD3 SMAD family member 3 2.62 0.00661
  SKP1 S-phase kinase-associated protein 1 2.54 0.00148
  SIAH1 seven in absentia homolog 1 (Drosophila) 2.46 0.00875
  DVL2 dishevelled, dsh homolog 2 (Drosophila) 2.31 0.00201
  BTRC beta-transducin repeat containing 2.18 0.00881
  NFATC3 
nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 3
2.02 0.0108
Hedgehog signaling pathway 
  BMP7 bone morphogenetic protein 7 9.89 0.00021
26
  ZIC2 Zic family member 2 (odd-paired homolog, Drosophila) 5.87 0.00298
  GLI2 GLI family zinc finger 2 3.84 0.00438
  GLI3 GLI family zinc finger 3 2.99 0.00925
  Sufu suppressor of fused homolog (Drosophila) 1.99 0.00651
Androgen receptor signaling pathway 
  AR androgen receptor 9.89 0.000486
  MED30 mediator complex subunit 30 2.63 0.001934
  MED17 mediator complex subunit 17 2.04 0.009345
  DAXX death-domain associated protein 1.83 0.010927
  THRAP3 thyroid hormone receptor associated protein 3 1.73 0.016438
pancreas on western blot. Of the epithelial-mesenchymal transition related markers, 
E-cadherin expression was detected in 1 case of SPNs, 3 out of 6 NETs, and 5 out 
of 6 PCAs by using E-cadherin. N-cadherin expression was found in 8 cases of 
SPNs, 4 out of 6 NETs. None of the six PCAs were assessed by western blot. 
Immunohistochemical analysis revealed characteristic β-catenin nuclear 
accumulation exclusively in all 14 SPNs, whereas no nuclear β-catenin expression 
was found in PCAs or NETs. Strong cytoplasmic WIF-1 expression, and strong 
nuclear expressions of GLI2 and androgen receptor were demonstrated in all 14 
SPNs (Figure 7C). In contrast to rare membranous E-cadherin expression in all of 
the 14 SPNs, N-cadherin expression was found in 12 ouf of SPNs. In 3 ouf of 6 
NETs and all of 6 PCAs, E-cadherin expression was detected by 
immunohistochemistry.
7. Distinct protein expression profiles of SPN
Additionally, protein expression profiling of solid-pseudopapillary neoplasm was 
performed by TMT labeling and LC-MS/MS (Figure 8A), and I integrated protein 
expression results with those of the mRNA expression. First, I identified 551 
proteins with high confidence (FDR<1%). Among them, 329 proteins (150 up-
regulated and 179 down-regulated) were further selected for quantitative analysis 
27
(Figure 8B). I chose 329 differentially expressed proteins with an SPN/normal ratio 
of 1.5 as cut-off, since fold ratio of β-catenin was 1.68. Among the identified 551 
proteins, 150 proteins were upregulated in the proteomics data, and 87 (58.0%) 
proteins were up-regulated in both the proteome and the mRNA expression analyses 
(Figure 8C). We found that proteins that are involved in Wnt/β- catenin signaling 
[DKK4 (8.06-fold), and CTNNB1 (1.68-fold)] or proteins that bind to β-catenin 
[FN1 (5.9-fold), SELENBP1 (4.99-fold), DDX5 (3.09-fold), YWHAZ (2.24-fold), 
NONO (1.89-fold), BGN (1.80-fold), hnRNPM (1.71-fold) and FUS (1.51-fold)] 
were up-regulated (Table 6). Furthermore, among the up-regulated proteins, 24 
(4.36% of 551 identified proteins) overlapped with the genes that were specifically 
up- regulated in SPNs on the mRNA array. I could not find specific signaling
Table 6. List of dysregulated proteins in SPNs
A) Up-regulated proteins in SPN
Gene 
Symbol
Protein 
SPN_T/N*
mRNA 
_SPN
interact
Gene 
Symbol
Protein 
SPN_T/N
mRNA 
_SPN
interact
CYB5B 8.93 4.71 - NPNT 2.47 4.47 -
NOTUM 8.49 52.98 - DLD 2.21 -1.39 -
DKK4 8.06 329.26 - RAN 2.17 6.46 AR
PKM2 6.81 10.10 - HSP90AA1 1.90 1.79 -
CAPS 6.49 5.10 - NONO 1.89 1.30 -
GSN 5.93 3.28 AR** MATR3 1.84 1.98 -
ENO2 5.25 21.11 - PSME2 1.84 2.34 -
SELENBP1 4.99 13.47 β*** HNRNPA1 1.81 2.75 AR
PDXK 4.82 12.12 - SFPQ 1.78 1.01 -
ACSS3 3.80 4.90 - HNRNPA2B1 1.74 1.02 β
MFAP2 3.77 3.03 - CTNNB1 1.68 4.38 AR
LSAMP 3.75 11.35 - NPM1 1.67 1.07 -
HK1 3.37 7.01 - TPM4 1.64 1.98 -
IGFBP7 3.21 4.69 - NOV 1.63 50.86 AR
SLC25A13 3.20 3.29 - PDHB 1.61 1.10 -
DDX5 3.09 2.53 - ALDH7A1 1.61 1.42 -
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PGK1 3.07 2.67 - GPI 1.59 1.60 -
NUMA1 3.00 1.33 - PAICS 1.55 4.51 -
CTSB 2.81 3.84 - FUS 1.51 2.19 β/AR
TUBB 2.79 3.09 -
B) Down-regulated proteins in SPN
Gene 
Symbol
Protein 
SPN_T/N
mRNA 
_SPN
interact
Gene 
Symbol
Protein 
SPN_T/N
mRNA 
_SPN
interact
GCG 0.03 -85.00 β IDH2 0.39 -3.99 -
TSC22D1 0.04 6.04 β HBB 0.41 -1.85 AR
GSTA1 0.05 -126.01 AR YBX1 0.43 1.35 AR
INS 0.09 -19.92 - HBA1 0.46 -3.00 AR
P4HB 0.11 -4.79 β AARS 0.47 -2.08 β
KRT8 0.12 -8.42 β/AR CALR 0.53 -1.24 AR
KRT7 0.13 -2.20 AR BLVRB 0.54 -2.50 AR
TPSAB1 0.14 -3.69 AR RPL22 0.57 -1.74 -
KRT18 0.16 -3.44 β/AR PGM1 0.63 1.43 -
FGG 0.16 -1.13 AR MSN 0.63 1.14 AR
HSPA5 0.25 -3.81 AR LDHB 0.63 -1.56 AR
DDT 0.32 -1.48 AR IQGAP1 0.63 1.31 β
ADH1B 0.33 -1.88 AR COL1A1 0.64 -1.45 -
TXNDC5 0.37 -2.98 β C4A 0.64 -1.05 AR
CYB5A 0.38 -9.94 β PDIA3 0.66 -1.05 β
RPN1 0.38 -1.10 -
*tumor/normal, **androgen receptor and *** β-catenin
pathways that were activated in SPNs according to the proteome data, however, I 
identified many proteins that interact to the key molecules of Wnt/β-catenin, AR, 
Notch and Hedgehog signaling pathways are up-regulated in our proteomic analysis, 
although key molecules involved in these activated pathways was not detected 
proteomic analysis. (Figure 8D).
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Figure 8. Proteomics analysis of solid-pseudopapillary neoplasm. Workflow 
overview of proteome identification and quantification (A), and workflow of 
proteomics data analysis (B). Venn diagrams showed overlap between the identified 
proteins and the mRNA expression data. Among 551 proteins matched with mRNA 
data, 150 proteins were up-regulated, and 179 proteins were downregulated. Among 
the 150 up-regulated proteins, 87 proteins (58.0%) showed the same tendency with 
mRNA expression. Among the 179 down-regulated proteins, 104 proteins (58.1%) 
showed the same tendency with mRNA expression (C). Schematic of protein 
expression profile of SPN for the genes known to interact to the key genes of the 
Wnt/β-catenin, androgen receptor, Notch and Hedgehog signaling pathways. The 
key genes of the activated signaling pathways in SPNs are marked with blue 
circular area. The intensity of red color in the box represents expressional value 
compared with those of non-neoplastic tissues. The grey color in the box denotes 
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that protein was not identified by our proteomics analysis. Among the 150 up-
regulated proteins in SPNs, we selected 45 proteins that are known to interact to the 
15 key molecules of four activated signaling pathways (D).
8. Overexpression of β-catenin mutants activates several molecules involved in 
Wnt/β-catenin signaling, Hedgehog signaling and androgen receptor signaling 
pathway
Mutant β-catenin vectors (S33A, S37A, T41A and S45A) resistant to GSK3β and 
CK1-dependent phosphorylation, which is essential to β-catenin degradation, were 
generated and used to identify gene subsets altered by constant activation of β-
catenin. HEK293 cells and RKO cells were transfected with each β-catenin
expression vector (wild-type, S33A, S37A, T41A, and S45A), and similar mRNA 
levels of β-catenin were confirmed by qRT-PCR (Figure 9A). Protein expression 
level of wild-type β-catenin, however, was lower than expression levels of other β-
catenin mutants, because of proteasome-dependent degradation of wild-type β-
catenin. We also validated protein expression levels of phosphorylated β-catenin 
mutants (S33, S37, T41 and S45) to verify whether or not these β-catenin mutants 
were phosphorylated. Phosphorylation of β-catenin at Ser-33, Ser-37, or Thr-41 was 
detected only in HEK293 and RKO cells transfected with wild-type β-catenin and a 
single β-catenin mutant (S45A), whereas phosphorylation of β-catenin at Ser-45 
was detected in HEK293 cells transfected with β-catenin mutants S33A, S37A and 
T41A (Figure 9B). Since nuclear localization of β-catenin is important to the action 
of activated β-catenin, localization of β-catenins from each construct was also 
visually validated by immunofluorescence microscopic analysis (Figure 9C). 
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Figure 9. Mutants of β-catenin resistant for phosphorylation increase Wnt 
activity compared to wild-type β-catenin. HEK293 cells and RKO cells were 
transfected with each β-catenin expression vectors (wild-type, S33A, S37A, T41A 
and S45A) and similar mRNA levels of β-catenin were confirmed by qRT-PCR (A). 
Total β-catenin and phosphorylated β-catenin were validated by western blot 
analysis (B). Localization of β-catenins from each construct was validated by 
immunofluorescence microscopic analysis. Wild-type β-catenin is localized in the 
cytoplasm, while β-catenin mutants are localized in the nucleus (C). To confirm if 
Wnt/β-catenin signaling activity is induced by mutant β-catenin, TOP-Flash (blue) 
or FOP-Flash (red) was used to measure luciferase activity. Luciferase activity in 
HEK293 transfected with β-catenin mutants was much higher than luciferase 
activity in HEK293 transfected with wild-type β-catenin (D).
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Figure 10. Overexpression of mutant β-catenin increased expression of 
molecules involved in Wnt/β-catenin signaling, Hedgehog signaling, androgen 
receptor signaling and epithelial-mesenchymal transition. Expression of WIF1, 
GLI2 and androgen receptor was increased, whereas E-cadherin was slightly 
reduced in HEK293 cells transfected with β-catenin mutants compared to the 
control (wild-type β-catenin). According to the mutation type of β-catenin, 
expression of WIF1 and androgen receptor in HEK293 cells transfected with mutant 
S45A were distinctively detected compared to the expression WIF1 and androgen 
receptor in HEK293 cells transfected with other β-catenin mutants (S33A, S37A 
and T41A) (A), whereas altered expressions of WIF1, androgen receptor and E-
cadherin were not detected in RKO transfected with wild-type or mutant types of β-
catenin (B). β-catenin mutants were similarly detected at total protein level, but 
expression of β-catenin were differently detected in cytoplasmic and nuclear 
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fraction. Expression of S33A mutant β-catenin was much higher than S45A mutant 
β-catenin in nuclear fraction, and expression of androgen receptor in HEK293 cells 
transfected with S33A was higher than in HEK293 cells transfected with S45A. 
Expression of E-cadherin was reduced in HEK293 cells transfected with β-catenin
mutants (S33A, S37A and T41A), while nuclear E-cadherin increased in HEK293 
cells transfected with mutant β-catenin (S45A) compared to wild-type β-catenin and 
the other β-catenin mutants (S33A, S37A and T41A) (C).
To confirm whether Wnt/β-catenin was induced by mutant β-catenin, TOP-Flash (a 
reporter construct that has eight copies of the consensus Lef/Tcf binding site) or 
FOP-Flash (a reporter construct that has eight copies of the mutated consensus 
Lef/Tcf binding site) was co-transfected into HEK293 cells with β-catenin. 
Luciferase activity was increased greatly in HEK293 cells transfected with mutant 
β-catenin, compared to empty vector. Also, luciferase activity in HEK293 cells
transfected with β-catenin mutants was much higher than luciferase activity in 
HEK293 cells transfected with wild-type β-catenin (Figure 9D). Next, the 
expression levels of proteins altered by transfected β-catenin mutants were 
evaluated, including in those involved in Wnt/β-catenin, Hedgehog, and androgen 
receptor signaling pathways (WIF1, RUVBL1, Axin, GLI2, androgen receptor, E-
cadherin, and N-cadherin). The expressions of WIF1, GLI2, and androgen receptor 
were increased, whereas E-cadherin expression was slightly reduced in HEK293 
cells transfected with β-catenin mutants, compared to the control (wild-type β-
catenin). Meanwhile, the expressions of WIF1 and androgen receptor in HEK293 
cells transfected with mutant S45A differed from those in HEK293 cells transfected 
with other β-catenin mutants (S33A, S37A, and T41A) (Figure 10A). The
expressions of WIF1, androgen receptor, and E-cadherin were not altered in RKO 
cells transfected with wild- type or mutant β-catenin (Figure 10B).
To measure nuclear forms of β-catenin, HEK293 cells transfected with wild-type 
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or mutant β-catenin were fractionated into cytoplasmic and nuclear fractions, and β-
catenin levels were determined by western blotting (Figure 10C). Although β-
catenin mutants showed similar total protein levels, the expressions of β-catenin
mutants differed in cytoplasmic and nuclear fractions. In the nucleus, the expression 
of S33A mutant β-catenin was much higher than that for S45A mutant β-catenin.
Also, the expression of androgen receptor in HEK293 cells transfected with S33A 
was greater than that in HEK293 cells transfected with S45A, demonstrating that 
mutant β-catenin induces greater nuclear androgen receptor expression than wild-
type β-catenin.
35
IV. DISCUSSION
β-catenin is a key molecule in Wnt/β-catenin signaling, which plays crucial roles
in tumorigenesis. In a various types of tumors, a high frequency of mutations in the 
genes controlling Wnt/β-catenin signaling has been reported. Mutations in APC are 
commonly found in colorectal cancers, and lead to the stabilization and 
accumulation of β-catenin in the cell. In this study, the mRNA expression profiles of 
colorectal cancers and pancreatic tumors, including solid-pseudopapillary 
neoplasms, were assessed to identify signaling pathways altered by accumulation of 
nuclear β-catenin. Colon cancer was selected as a model of nuclear β-catenin
overexpression resulting from alterations in genes involved in β-catenin degradation, 
and SPNs were chosen as a model of nuclear β-catenin overexpression induced by 
β-catenin mutation. In unsupervised clustering samples, analysis of expression 
profiles for colorectal tumors indicated that tumors with high nuclear β-catenin 
(>30%) are randomly distributed. Therefore, the present study attempted to identify
differentially expressed genes (DEGs) exclusively in tumors showing nuclear β-
catenin expression, compared to tumors showing negative expression of nuclear β-
catenin. As nuclear accumulation of β-catenin can be achieved with β-catenin
mutation and mutations in genes involved in β-catenin degradation, such as APC. β-
catenin mutation analysis was performed to verify mutation status of β-catenin in 
colon cancer samples from about 100 cases. In doing so, only two cases showed β-
catenin mutation in exon 3, and these two cases were not positioned in the same 
group clustered by complete linkage analysis. Thus, by excluding these two cases, 
the present study was able to analyze differential expression of genes in colon 
cancers related to nuclear accumulation of β-catenin driven by inhibition of β-
catenin degradation, such as that associated with APC mutations, not by mutation in 
β-catenin. The results thereof revealed 15 different groups of DEGs involved in 
Wnt/β-catenin, Notch, and Hedgehog signaling pathway, as well as extracellular 
matrix (ECM)-interactions.
In analysis of nuclear β-catenin staining and metastasis in colon cancer tissues, 
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patients with metastasis showed higher percentages of nuclear β-catenin staining. 
Moreover, tumors with the greater expression of nuclear β-catenin showed the 
greater metastatic potential. Interestingly, a previous study on colorectal tumors 
identified DEGs in the invasive front of tumors (related to nuclear expression of β-
catenin), compared to the tumor center (related to cytoplasmic expression of β-
catenin). The identified DEGs were further found to be related to cell adhesion, 
invasion, and EMT.31 Although the present study did not distinguish between the 
invasive front and tumor center, the DEGs noted in tumors with high nuclear β-
catenin expression were found to be involved in ECM-interaction and cell-cell 
adhesion.
Nevertheless, even if analysis of gene expression profiles in the colorectal cancers 
exhibiting nuclear β-catenin expression were to show up-regulated genes to be 
involved in several signaling pathways, the amounts of nuclear β-catenin expression 
are not high enough to explain the tumorigenesis of colon cancers, since the 
frequency of β-catenin mutation is about 5% and colorectal tumorigenesis is a 
complicated mechanism affected by mutations of other genes, such as APC and 
KRAS.32,33
Solid-pseudopapillary neoplasm of the pancreas is a rare pancreatic tumor, which 
has an activating β-catenin mutation, making it a good model for identifying gene 
subsets and signaling pathways induced by β-catenin mutation. Unsupervised 
hierarchical clustering analysis of DEGs in 31 microarrays grouped non-neoplastic 
tissues, SPNs and other pancreatic tumors (neuroendocrine tumors and pancreatic 
adenocarcinomas). Groups were separated according to tumor types, which 
suggested that tumors with β-catenin mutation could be characterized by unique 
gene expression patterns. Although expression of β-catenin was slightly increased in 
neuroendocrine tumors and pancreatic adenocarcinomas, compared to non-
neoplastic tissues, gene expression profiles and the immunophenotypes of SPNs 
were clearly different from other pancreatic tumors. This result suggests that SPN-
specific mRNA is affected by nuclear β-catenin, not merely β-catenin
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overexpression.
In accordance with results in this study, previous studies on SPN have reported 
activating CTNNB1 mutations and abnormal β-catenin nuclear accumulation due to 
inhibition of its degradation. Consequently, activation of downstream β-catenin
targets was expected. CTNNB1 mutation in SPN is heterozygous and many genes 
encoding components of the Wnt/β-catenin signaling pathway have been shown to 
be upregulated in SPN by this study and others.34 Specifically, studies have found 
that mRNA levels of CTNNB1 are approximately three to four-fold upregulated in 
SPNs and that β-catenin protein accumulates in nucleus. The proportion of mutant 
to wild-type β-catenin protein in the nucleus and its effects on downstream targets 
should be further studied.
The present study compared gene expression profiles of SPN with non-neoplastic 
pancreas or other pancreatic tumors. As expected, Wnt/β-catenin signaling pathway 
was activated in SPNs due to β-catenin mutations and abnormal nuclear 
accumulation of β-catenin. Besides the Wnt/β-catenin pathway, SPNs also exhibited
upregulation of genes involved in the activation of the Hedgehog and androgen 
receptor signaling pathways. Based on the analysis of upregulated genes in SPN, I
propose that SPNs can be characterized by activation of the Wnt/β-catenin, 
Hedgehog, and androgen receptor signaling pathways. At present, only one report 
has attempted to outline the gene expression profiles of SPNs. The study showed 
that the Wnt/β-catenin and Notch signaling pathways are involved in SPN.34
Consistent with this, the present study demonstrated that genes in the Notch 
signaling pathway are differentially expressed in SPNs, compared to non-neoplastic 
pancreatic tissues. However, because these genes were also differentially expressed 
in pancreatic adenocarcinomas and/or neuroendocrine tumors, the Notch signaling 
pathway was not regarded as being distinctively activated in SPNs and, therefore, 
not related to β-catenin mutation. Instead, the Hedgehog signaling pathway was 
significantly activated in SPNs alone. The Notch and Hedgehog signaling pathways 
are closely related to the Wnt/β-catenin pathway, with many components in 
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common.35,36 The Notch signaling pathway is also activated in colorectal cancers 
exhibiting high amounts of nuclear β-catenin expression. Previous studies have 
demonstrated that nuclear accumulation of β-catenin induces the expression of hes1,
which plays an important role in Notch signaling and is associated with the Notch1 
intracellular domain (N1IC).37 This suggests that activation of Notch signaling may 
be associated with β-catenin overexpression, not with β-catenin mutation.
As a novel finding, activation of the androgen receptor signaling pathway was 
discovered in SPNs. Indeed, increased androgen receptor (AR) expression was 
noted at the transcriptional and translational levels. Studies have shown that AR
binds to the armadillo repeat domain of β-catenin and enhances the nuclear
localization thereof.38-40 As well, increased AR-dependent transcriptional activity
has been reported in prostatic tumors with CTNNB1 mutations.41 However, no direct 
relationship between activation of Wnt/β-catenin and AR signaling pathways has 
been reported. For the first time, a high level of nuclear AR expression was noted 
in SPNs (n=14) in this study. In addition, increased nuclear androgen receptor was 
detected in cells transfected with mutant β-catenin relative to cells transfected with 
wild-type β-catenin. Crosstalk between AR and β-catenin has been well documented
in prostate cancers.42,43 Some studies have also reported that AR induces nuclear 
localization of β-catenin and activates β-catenin-mediated transcription, while the 
others have demonstrated that interaction between AR and β-catenin is necessary for 
co-translocation. In this study, nuclear localization of AR was found to be affected 
by overexpression of β-catenin in the nucleus as a result of β-catenin mutation.
Additionally, genes specifically altered in SPNs were found to be linked to EMT. 
Marked down-regulation of E-cadherin (CDH1) and up-regulation of N-cadherin 
(CDH2) and vimentin in SPNs were validated by western blotting. These findings 
are in accordance with the rare epithelial differentiation observed in SPN tumor 
cells. Interestingly, up-regulation of the EMT regulator genes TWIST2 and ZEB2
was also observed. The expression of EMT-related genes is closely linked with 
activation of the Wnt/β-catenin, Notch, and Hedgehog signaling pathways.36,44-48
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Wnt signaling promotes EMT, which is associated with cancer progression via β-
catenin-mediated transcription.49 In Hedgehog signaling, ligand binding to patched 
receptor activates glioma (GLI) transcription factors, and subsequently induces 
EMT-related gene expression and loss of E-cadherin. Additionally, the Notch 
intracellular domain has been considered as an EMT regulator, such as Snail and 
Slug,50,51 although some studies suggest that Notch signaling is not sufficient to 
completely induce EMT.52 Accordingly, SPN can be characterized by activation of 
Wnt/β-catenin, Hedgehog, and androgen receptor signaling pathways, as well as 
EMT.
To evaluate the effect of β-catenin in vitro, four mutant β-catenin constructs (S33A, 
S37A, T41A and S45A) were generated, and the expression levels of selected genes 
activated in SPNs after transfection with the β-catenin constructs were assessed. In 
doing so, the protein expressions of WIF1, GLI2, AR, and E-cadherin were found to 
be dysregulated in cells transfected with the mutant β-catenin constructs, compared 
to cells transfected with wild-type β-catenin. Interestingly, transfected β-catenin
mutants showed different effects on the translocation of AR into the nucleus. Cells 
transfected with mutant constructs S33A, S37A, and T41A showed higher nuclear 
AR expression than cells transfected with the wild-type β-catenin construct.
Meanwhile, cells transfected with mutant β-catenin-S45A showed lower AR
expression in nucleus compared to cells transfected with other mutant constructs of 
β-catenin. Considering β-catenin S45A is not phosphorylated by CK1, β-catenin
would be expected to be stabilized, as serial phosphorylation at codons 33, 37, and
41 by GSK3β would be inhibited. Analysis of gene expressions in HEK293 cells 
expressing each β-catenin construct demonstrated that β-catenin mutantion activates 
genes involved in Wnt/β-catenin, and Hedgehog signaling pathway, as well as cell-
cell adhesion. Biological processes, including cell-cell adhesion and migration,
were also activated in colon cancers with high nuclear β-catenin expression. In 
HEK293 cells, Notch signaling was not distinctly activated by β-catenin mutants
alone, as it was also activated by wild-type β-catenin. Thus, activation of Notch
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signaling may not be SPN-specific, because it is also found to be activated in 
neuroendocrine tumors and pancreatic adenocarcinomas in which (cytoplasmic) β-
catenin expression is up-regulated, compared to non-neoplastic tissue without β-
catenin mutation. Notch signaling was also detected as an activated pathway in 
colon cancers showing high β-catenin expression in the nucleus. Thus, activation of 
Notch signaling in colorectal cancer and SPN is more likely caused by 
overexpression and accumulation of β-catenin, rather than β-catenin mutation. 
Studies suggest that several genes involved in a specific pathway can also play 
additional roles in another pathway.53-57 By combining the results of the present 
study, which evaluated colon cancer, SPNs and HEK293 cells transfected with β-
catenin constructs, several intermediate genes that connect Wnt/β-catenin signaling 
with Hedgehog, Notch, and androgen receptor signaling can be selected. I finally 
selected about 30 genes that could be expected to connect one of these pathways
with another. 
For future study, selected genes should be narrowed down based on the hypothesis 
that nuclear β-catenin expression leads to the activation of Notch and Hedgehog 
signaling pathway via genes concomitantly involved in multiple-pathways. Also, 
the effects of regulating master genes on the Notch and Hedgehog pathways should
also be investigated in various disease models.  
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V. CONCLUSION
In conclusion, nuclear β-catenin overexpression affects the signaling pathways of
Wnt/β-catenin, Notch, Hedgehog and androgen receptor signaling pathway
according to the disease model. 
In my study, I found;
1. Nuclear β-catenin overexpression plays roles in Wnt/β-catenin signaling pathway.
2. Notch and Hedgehog signaling pathways are identified as novel pathways
relevant with nuclear β-catenin overexpression in both colon cancers and SPN.
3. Androgen receptor signaling pathway is identified as characteristic and up-
regulated pathway in SPN.
In summary, nuclear β-catenin commonly or selectively affects the signaling 
pathways such as Wnt/β-catenin, Notch, Hedgehog and androgen receptor signaling 
pathway according to the disease model.
Figure 11. A schematic model of the nuclear β-catenin-related network 
describing potential intermediate genes associated with the Wnt/β-catenin, 
Notch, Hedgehog, and androgen receptor signaling pathways. With β-catenin 
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located in the center, genes up-regulated in SPN, colon cancer or in vitro model are 
shown around Wnt/β-catenin, Notch, Hedgehog, and androgen receptor signaling 
pathways (A). Simplified version of networks including activated pathways in colon 
cancer, pancreatic tumors and cell lines expressing mutant β-catenin (B).
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ABSTRACT (IN KOREAN)
핵내 베타카테닌 과발현에 의한 암 발생 신호전달체계 규명
<지도교수 김 호 근> 
연세대학교 대학원 의과학과
박 민 희
베타카테닌의 핵내 과발현과 돌연변이는 대장암, 유방암, 폐암
등의 다양한 암에서 보고되어왔다. 대부분의 베타카테닌
돌연변이는 CTNNB1 유전자의 3 번 exon 에 위치하고 있으며, 이
돌연변이는 베타카테닌의 분해 복합체를 억제함으로써
베타카테닌의 안정화를 유발한다. 대장암에서, APC 돌연변이는
대장암의 70-80%에서 발견되고 베타카테닌 돌연변이는 APC 
유전자와 상호 배타적으로 약 5%의 대장암에서 발견된다. 변화된
Wnt 신호전달체계에 APC 돌연변이가 관련되어 있다는 연구는 많이
보고되었지만, 대장암에서 변화된 Wnt 신호전달체계와
베타카테닌의 돌연변이 사이의 기능적 연관성은 아직 완전히
설명되지 않았다. 또한 다른 종양에서의 베타카테닌 돌연변이의
분자생물학적 중요성 역시 아직 완전히 이해되지 않았다. 췌장
고형성 가성유두상 종양 (solid-pseudopapillary neoplasm, 
SPN)은 거의 모든 예에서 베타카테닌 3 번 exon 에 체세포
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돌연변이를 갖고 있으며, 이는 비정상적인 베타카테닌의 핵내
과발현을 유발한다. 그러나 베타카테닌의 돌연변이와 Wnt 
신호전달체계의 활성화는 SPN 발생의 원인으로 알려져 있지만
분자생물학적 조절 연관성에 대한 연구는 미비하다. 종양에서
베타카테닌의 핵내 축적에 의해 변하는 신호전달체계를 동정하기
위해서 연구모델로 대장암과 SPN 을 선택하였다. 베타카테닌
돌연변이는 대장암 일부의 발생에 관여하는 반면, SPN 의 발생은
베타카테닌 돌연변이에 의해서 유발되기에 대장암을 핵내
베타카테닌 과발현이 베타카테닌을 분해하는 유전자의 이상으로
초래된 불균질 모델로, SPN 은 베타카테닌 돌연변이에 의해
초래되는 균질모델로 정하고 실험을 진행하였다. 대장암에서 핵에
위치한 베타카테닌이 일정하게 발현하지 않기 때문에, 우선
대장암을 핵에 위치한 베타카테닌의 비율을 기준으로 나누고
비율에 따라 부분집합으로 대장암을 분류하였다. 베타카테닌의
핵발현이 높은 (30% 이상) 대장암의 mRNA 발현 특성을 분석한
결과 핵에 위치한 베타카테닌은 대장암에서 Wnt, Notch 및
Hedgehog 신호전달계 뿐만 아니라 상피-간엽 전환 (Epithelial-
Mesenchymal Transition. EMT) 수용체와의 상호작용에 관여하는
유전자를 활성화시켰다. 거의 모든 종양세포에서 베타카테닌이
핵에 발현하는 질병 모델에서 관련한 유전자 집합을 발굴하기
위해, SPN 과 다른 종류의 췌장암 (췌장 선암종, 췌장내분비 종양) 
에 대해 유전자 발현 분석을 수행한 결과 mRNA 발현의 집단화
분석은 SPN 과 다른 종류의 췌장암을 구별하였다. 전 예에서
베타카테닌 돌연변이와 핵 발현을 보이는 SPN 에서 발현차이를
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보이는 유전자들은 Wnt, Hedgehog 그리고 androgen receptor 
신호전달체계와 관련이 있었고, 아울러 EMT 와 관련 유전자들이
활성화되어 있다. 
마지막으로 돌연변이형 베타카테닌에 의해 직접 변화되는
신호전달체계와 유전자들을 동정하기 위하여 두가지 세포주를
이용하여 여러 종류의 돌연변이형 베타카테닌 벡터를 직접 도입한
결과, androgen receptor 가 핵으로 이동하는 것과 Wnt, Notch, 
Hedgehog 신호전달계에 속한 유전자들의 발현이 증가 하는 사실을
확인하였다. 
본 실험을 통하여 나는 베타카테닌의 돌연변이에 의한
베타카테닌의 핵내 축적은 Wnt, Notch, Hedgehog 그리고 androgen 
receptor 신호전달체계의 활성화를 시켜 대장암 일부와 SPN 종양의
발생과 진행에 관여한다고 결론지었다.
-----------------------------------------------------------------------------------------------------
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